This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark UCB’s performance against key rivals in the ethical pharmaceutical sector
Assess how M&A has shaped UCB into a next generation bio-pharmaceutical player
Assess UCB’s market leading position in the epilepsy treatment segment and the use of life cycle management in a bid to retain this status
Analysis service - track your competitors, and identify new partners. Qualitative and quantitative company and portfolio analysis for the leading pharmaceutical and biotechnology companies in the US, Europe and Japan, and detailed analysis of key market sectors with detailed coverage of key players.Including analysis of their company strategy, product portfolio, and development pipeline, with forecasting.
